Global Patent Index - EP 1937815 A4

EP 1937815 A4 20100317 - METHODS AND COMPOSITIONS FOR MODULATING TUMOR CELL ACTIVITY

Title (en)

METHODS AND COMPOSITIONS FOR MODULATING TUMOR CELL ACTIVITY

Title (de)

VERFAHREN UND ZUSAMMENSETZUNGEN ZUR MODULATION DER TUMORZELLAKTIVITÄT

Title (fr)

MÉTHODES ET COMPOSITIONS PERMETTANT DE MODULER L'ACTIVITÉ DES CELLULES TUMORALES

Publication

EP 1937815 A4 20100317 (EN)

Application

EP 06790678 A 20060913

Priority

  • CA 2006001505 W 20060913
  • US 71608605 P 20050913

Abstract (en)

[origin: WO2007030930A1] Antibodies which target clusterin, a protein involved in the epithelial-to-mesenchymal transition of carcinoma cells, are identified and characterized. The antibodies may be used to modulate tumour cell activity through binding to clusterin.

IPC 8 full level

C12N 15/13 (2006.01); A61K 31/00 (2006.01); A61K 38/17 (2006.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61P 35/00 (2006.01); C07K 16/18 (2006.01); C12N 15/12 (2006.01); G01N 33/53 (2006.01); G01N 33/574 (2006.01)

CPC (source: EP US)

A61K 31/00 (2013.01 - EP US); A61P 35/00 (2017.12 - EP); A61P 35/04 (2017.12 - EP); C07K 16/18 (2013.01 - US); C07K 16/30 (2013.01 - EP US); G01N 33/574 (2013.01 - EP US); C07K 2317/34 (2013.01 - EP US); C07K 2317/56 (2013.01 - EP US); C07K 2317/565 (2013.01 - EP US); C07K 2317/76 (2013.01 - EP US)

Citation (search report)

  • [X] US 2005152903 A1 20050714 - NEWMAN WALTER [US], et al
  • [X] WO 2005060457 A2 20050707 - PROTEIN DESIGN LABS INC [US], et al
  • [X] WO 2004050707 A2 20040617 - NEMOD BIOTHERAPEUTICS GMBH & C [DE], et al
  • [X] WO 2005080434 A1 20050901 - UNIV ROMA [IT], et al
  • [A] WO 0034469 A1 20000615 - UNIV NEW YORK STATE RES FOUND [US]
  • [X] TROUGAKOS ET AL: "Differential effects of clusterin/apolipoprotein J on cellular growth and survival", FREE RADICAL BIOLOGY AND MEDICINE, ELSEVIER SCIENCE, vol. 38, no. 4, 15 February 2005 (2005-02-15), pages 436 - 449, XP005181698, ISSN: 0891-5849
  • [X] JULY L V ET AL: "CLUSTERIN EXPRESSION IS SIGNIFICANTLY ENHANCED IN PROSTATE CANCER CELLS FOLLOWING ANDROGEN WITHDRAWAL THERAPY", PROSTATE, WILEY-LISS, NEW YORK, NY, US, vol. 50, no. 3, 15 February 2002 (2002-02-15), pages 179 - 188, XP009024853, ISSN: 0270-4137
  • [X] CERVELLERA M ET AL: "Direct transactivation of the anti-apoptotic gene apolipoprotein J (clusterin) by B-MYB.", THE JOURNAL OF BIOLOGICAL CHEMISTRY 14 JUL 2000, vol. 275, no. 28, 14 July 2000 (2000-07-14), pages 21055 - 21060, XP002531083, ISSN: 0021-9258
  • [X] SANTA CRUZ BIOTECHNOLOGY INC.: "Clusterin-alpha (C-18): sc-6419", SANTA CRUZ BIOTECHNOLOGY INC. CATALOG, 1999, pages 1, XP002531084
  • [X] SANTA CRUZ BIOTECHNOLOGY INC.: "clusterin-alpha (B-5): sc-5289", SANTA CRUZ BIOTECHNOLOGY INC. CATALOG, 2004, pages 1, XP002531085
  • [T] CHOU TEH-YING ET AL: "Clusterin silencing in human lung adenocarcinoma cells induces a mesenchymal-to-epithelial transition through modulating the ERK/Slug pathway.", CELLULAR SIGNALLING MAY 2009, vol. 21, no. 5, May 2009 (2009-05-01), pages 704 - 711, XP002531086, ISSN: 1873-3913
  • [X] CHI KIM N ET AL: "A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer.", JOURNAL OF THE NATIONAL CANCER INSTITUTE 7 SEP 2005, vol. 97, no. 17, 7 September 2005 (2005-09-07), pages 1287 - 1296, XP002531087, ISSN: 1460-2105
  • [A] ZHOU WEI ET AL: "A novel anti-proliferative property of clusterin in prostate cancer cells.", LIFE SCIENCES 22 NOV 2002, vol. 72, no. 1, 22 November 2002 (2002-11-22), pages 11 - 21, XP002531088, ISSN: 0024-3205
  • [X] DATABASE EMBL-EBI [online] 20 June 2005 (2005-06-20), STAELENS: "Humanization by variable domain resurfacing and grafting on a human IgG4, using a new approach for determination of non human like surface accesible framework residues based on homology modelling of variable domains", XP002531089, accession no. AJ965435 Database accession no. AJ965435
  • [X] DATABASE EMBL-EBI 9 August 1999 (1999-08-09), VAN DER KEYL: "mus musculus anti fluorescein Ig light chain mRNA", XP002531090, accession no. AF139227 Database accession no. AF139227
  • See references of WO 2007030930A1

Designated contracting state (EPC)

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

DOCDB simple family (publication)

WO 2007030930 A1 20070322; AU 2006291990 A1 20070322; AU 2006291990 B2 20120531; CA 2621363 A1 20070322; CA 2621363 C 20150707; DK 1937815 T3 20150803; EP 1937815 A1 20080702; EP 1937815 A4 20100317; EP 1937815 B1 20150513; ES 2543341 T3 20150818; JP 2009507476 A 20090226; JP 2013155185 A 20130815; JP 5376948 B2 20131225; JP 5759503 B2 20150805; US 2009104215 A1 20090423; US 2011033471 A1 20110210; US 2012071635 A1 20120322; US 2015111250 A1 20150423; US 8044179 B2 20111025; US 8426562 B2 20130423

DOCDB simple family (application)

CA 2006001505 W 20060913; AU 2006291990 A 20060913; CA 2621363 A 20060913; DK 06790678 T 20060913; EP 06790678 A 20060913; ES 06790678 T 20060913; JP 2008529439 A 20060913; JP 2013081236 A 20130409; US 201113268020 A 20111007; US 201414495020 A 20140924; US 84644010 A 20100729; US 99145906 A 20060913